Jean Sibilia Selected Research

Necrosis

11/2022	Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases).
1/2019	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
1/2019	Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.
5/2015	In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome.
4/2015	Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study.
12/2012	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice.
1/2009	Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
3/2007	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
1/2005	Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
6/2004	Impaired release of IL-18 from fibroblast-like synoviocytes activated with protein I/II, a pathogen-associated molecular pattern from oral streptococci, results from defective translation of IL-18 mRNA in pro-IL-18.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean Sibilia Research Topics

Disease

78	Rheumatoid Arthritis 09/2023 - 02/2002
24	Inflammation (Inflammations) 09/2023 - 03/2003
22	Arthritis (Polyarthritis) 10/2022 - 07/2002
16	Autoimmune Diseases (Autoimmune Disease) 01/2023 - 12/2002
14	Myositis (Idiopathic Inflammatory Myopathies) 01/2022 - 12/2006
14	Infections 12/2021 - 04/2004
13	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 01/2005
13	Systemic Scleroderma (Systemic Sclerosis) 02/2020 - 12/2002
11	COVID-19 11/2022 - 01/2020
11	Fatigue 01/2022 - 01/2009
10	Necrosis 11/2022 - 06/2004
10	Pain (Aches) 01/2020 - 04/2002
9	Neoplasms (Cancer) 01/2020 - 01/2005
6	Joint Diseases (Joint Disease) 09/2021 - 07/2002
6	Muscular Diseases (Myopathy) 01/2018 - 10/2010
5	Rheumatic Diseases (Rheumatism) 10/2021 - 02/2008
5	Osteoarthritis 09/2021 - 06/2004
5	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 12/2018 - 03/2003
4	Vasculitis (Vasculitides) 02/2020 - 09/2011
4	Dermatomyositis (Dermatopolymyositis) 01/2019 - 07/2011
4	Antisynthetase syndrome 01/2018 - 12/2012
4	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 09/2015 - 04/2003
4	Ulcer 02/2008 - 11/2003
3	Proteinuria 01/2023 - 07/2003
3	Reactive Arthritis (Reiter Disease) 09/2021 - 01/2008
3	Takayasu Arteritis (Arteritis, Takayasu's) 10/2020 - 05/2012
3	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 10/2020 - 01/2018
3	Pneumonia (Pneumonitis) 01/2020 - 04/2002
3	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2020 - 01/2011
3	Synovitis 01/2019 - 12/2005
3	Neutropenia 09/2017 - 04/2002
3	Sepsis (Septicemia) 09/2017 - 08/2002
3	Agranulocytosis (Granulocytopenia) 01/2017 - 04/2002
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2015 - 03/2011
3	Myocardial Infarction 09/2006 - 03/2004
3	Hemorrhage 04/2004 - 11/2003
2	Lymphoma (Lymphomas) 10/2023 - 06/2002
2	Psoriatic Arthritis 09/2021 - 05/2011
2	Glomerulonephritis 02/2020 - 01/2019
2	Multiple Sclerosis 01/2020 - 03/2012

Drug/Important Bio-Agent (IBA)

33	Rituximab (Mabthera)FDA Link 10/2020 - 10/2008
18	Methotrexate (Mexate)FDA LinkGeneric 01/2023 - 06/2002
18	AntibodiesIBA 01/2022 - 01/2006
17	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2017 - 07/2003
15	tocilizumab (atlizumab)FDA Link 05/2021 - 06/2010
14	Abatacept (Orencia)FDA Link 11/2022 - 08/2005
13	Antirheumatic Agents (DMARD)IBA 01/2020 - 07/2006
13	AutoantibodiesIBA 10/2019 - 03/2003
11	Proteins (Proteins, Gene)FDA Link 01/2023 - 07/2003
10	CytokinesIBA 10/2022 - 06/2004
9	Infliximab (Remicade)FDA Link 10/2020 - 07/2003
8	GlucocorticoidsIBA 10/2021 - 07/2006
8	Biomarkers (Surrogate Marker)IBA 09/2021 - 04/2011
8	Etanercept (Enbrel)FDA Link 07/2014 - 04/2003
7	B-Cell Activating FactorIBA 11/2022 - 01/2006
7	Interleukin-6 (Interleukin 6)IBA 01/2020 - 07/2003
7	ametantrone (HAQ)IBA 01/2019 - 11/2003
6	AntigensIBA 01/2023 - 11/2004
6	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020 - 11/2003
5	Immunoglobulin G (IgG)IBA 01/2023 - 03/2003
5	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2022 - 03/2003
5	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 02/2022 - 07/2014
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 08/2002
5	Rheumatoid FactorIBA 10/2013 - 08/2003
4	VaccinesIBA 10/2022 - 06/2017
4	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 10/2020 - 10/2013
4	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 12/2006
4	InterferonsIBA 01/2020 - 05/2010
4	Tumor Necrosis Factor InhibitorsIBA 09/2019 - 12/2012
4	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2017 - 06/2013
4	SteroidsIBA 06/2017 - 07/2002
4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 09/2015 - 09/2006
4	Peptides (Polypeptides)IBA 05/2015 - 11/2004
4	Monoclonal AntibodiesIBA 05/2015 - 10/2008
4	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 11/2013 - 12/2006
3	LigandsIBA 10/2023 - 01/2005
3	micaIBA 09/2021 - 06/2007
3	Imiquimod (Aldara)FDA LinkGeneric 01/2020 - 01/2016
3	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020 - 04/2015
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2017 - 04/2002
3	C-Reactive ProteinIBA 12/2016 - 11/2003
3	Ligases (Synthetase)IBA 07/2015 - 12/2006
3	Adalimumab (Humira)FDA Link 07/2014 - 11/2009
3	cyclic citrullinated peptideIBA 10/2013 - 01/2006
3	Antinuclear AntibodiesIBA 03/2010 - 01/2005
2	Intravenous Immunoglobulins (IVIG)FDA Link 01/2023 - 09/2011
2	anti-dsDNA autoantibodyIBA 01/2023 - 01/2019
2	InterleukinsIBA 11/2022 - 06/2004
2	Prostaglandins AIBA 01/2022 - 08/2010
2	Estrogens (Estrogen)FDA Link 01/2022 - 01/2021
2	COVID-19 VaccinesIBA 12/2021 - 10/2021
2	Calcium PyrophosphateIBA 09/2021 - 03/2013
2	Uric Acid (Urate)IBA 09/2021 - 01/2020
2	CholesterolIBA 05/2021 - 07/2006
2	rheinIBA 01/2021 - 01/2019
2	Antimalarials (Antimalarial Agents)IBA 01/2021 - 08/2018
2	Vitamin D FDA LinkGeneric 01/2020 - 11/2018

Therapy/Procedure

42	Therapeutics 11/2022 - 02/2002
8	Biological Therapy 01/2019 - 12/2005
3	Contraindications 03/2012 - 07/2006